BioSymetrics is impacting every stage of drug discovery and pharmaceutical research. Roll-over the hot spots below to see how.
TARGET-BASED DRUG DISCOVERY
Our target-based approach leverages computational and experimental processes to better predict in vivo efficacy and off-target effects.
PHENOTYPE-BASED DRUG DISCOVERY
The Contingent-AI™ computational framework begins with phenotypic screens as input, and predicts molecular mechanism, shortening timelines for target/mechanism identification.
- Dynamically reduces bias from experimental datasets, including from high-content screening
- Automated preprocessing of disparate data types (e.g. HCS, proteomics, genomics / transcriptomics) and data sources for faster discovery
In Vivo Phenotypic Barcoding
- We leverage a multi-dimensional “barcode” of in vivo phenotypic characteristics predictive of potential clinical applications and toxicity
AI DRUG DISCOVERY
BioSymetrics Combines Experimental and Machine Learning Methods to Enrich Target-Based Drug Discovery and Shorten Timelines for Phenotype-Based Drug Discovery
Life science companies tend focus on machine learning, ignoring the impact of the decisions they made in collecting and processing their data.
BioSymetrics has built a fundamentally different approach to Data Science, optimizing every step of the pharmaceutical research process using Contingent-AI™.
The result: less time spent in data processing, easier data integration, more accurate results for diagnostics and drug discovery, as well as truly autonomous capabilities for precision medicine
“BioSymetrics is unique in its focus on efficient pre-processing, enabling more transparent model building in biomedicine. We’re excited to be users of the platform.”Dr. Eric SchadtFounder and CEO, Sema4
“BioSymetrics has supported us in a variety of projects in different settings. In health insurance, their platform saved us months of man hours and approximately $6.4 million (£5-million) annually … the use of Augusta enabled the company to drive faster, more accurate and meaningful innovation.”Matt HickeyFounder and CEO, Intacare